PATIENT INFORMATION

MY TREATMENT WITH MAVIRET®

Everything you need to know about the medicine and its use.



abbvie

MAVIRET®
Glecaprevir/Pibrentasvir



MAVIRET® FOR THE TARGETED TREATMENT OF HEPATITIS C INFECTION

Your doctor has prescribed MAVIRET® to treat hepatitis C, an infectious disease of the liver caused by the hepatitis C virus (HCV).

MAVIRET® is approved for the treatment of acute and chronic hepatitis C infection. Acute hepatitis C refers to the disease during the first six months after infection with the virus. If the virus remains in the body after the first six months, it is considered chronic (long-term) hepatitis C. The infection can be cured in both the acute and chronic stages.

MAVIRET® is available for adults as film-coated tablets. MAVIRET® is available for children aged three years and older as coated granules. Each tablet and the granules contain a combination of the active ingredients glecaprevir and pibrentasvir.

MECHANISM OF ACTION

MAVIRET® is a direct-acting antiviral (DAA) effective against all common types of viruses that can cause hepatitis C infection.

- Its active ingredients inhibit certain proteins that the virus needs in order to multiply in the liver.
- It can therefore no longer infect any new liver cells.
- The infection is effectively treated, and the hepatitis C virus is completely eliminated from the body.

SIDE EFFECTS

Very common side effects of MAVIRET® are headache and fatigue.

- Please contact your doctor or pharmacist if you experience any symptoms during your treatment with MAVIRET®.
- You should also contact them if you notice any other unusual symptoms or changes while taking MAVIRET®.
- You can also report side effects directly via the national reporting system for Germany: **Federal Institute for Drugs and Medical Devices, Dept. Pharmacovigilance, Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn**

INTERACTIONS

Interactions between MAVIRET® and other medicines are uncommon. However, some medicines must not be taken with MAVIRET®, or only under medical supervision.

Therefore, before starting treatment with MAVIRET®, tell your doctor which medicines you are taking regularly or occasionally, or have recently taken.

You should also mention any over-the-counter products, such as St. John‘s wort. This information is important for your doctor in order to provide you with appropriate advice.

BLOOD TESTS

Before, during, and after your treatment with MAVIRET®, a blood sample will usually be taken and analyzed in a laboratory. Based on the results, your doctor can

- decide whether you should take the medicine;
- determine the appropriate duration of treatment;
- confirm that you no longer carry hepatitis C virus particles in your body and that the treatment has been successful.



The earlier an infection is detected, the sooner targeted treatment can prevent liver damage.

HEPATITIS C: CURABLE THANKS TO MODERN TREATMENTS

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV). The virus enters the body through blood-to-blood contact and multiplies in liver cells. If left untreated, the infection can severely damage the organ over the course of the disease.

HEPATITIS C IS CURABLE

With early and targeted treatment, a hepatitis C infection can now be cured in over 95 percent of cases.

- Treatment usually lasts only 8–12 weeks.
- The treatment is well tolerated and has few side effects.
- Only a daily dose of tablets is needed for effective treatment.
- Alcohol consumption, drug use, or substitution treatment do not prevent treatment.

DETECTING HEPATITIS C EARLY

Early symptoms of hepatitis C are usually flu-like. Pain in the upper right abdomen may also occur.

- If you want to know whether you have an infection, you can, for example, get tested for HCV at your general practitioner's office, the public health department, or counseling centers.
- If you are covered by statutory health insurance and are aged 35 or older, you are eligible for a one-time hepatitis C test as part of a general health check-up (Check-up 35). The costs for Check-up 35 are usually covered by health insurance.



INSTRUCTIONS FOR TAKING MAVIRET®

For adults and children aged 12 years and older with a body weight of at least 45 kg, the recommended daily dose is three MAVIRET® tablets containing 100 mg glecaprevir and 40 mg pibrentasvir. The three tablets are supplied in a blister pack. They are taken together as a daily dose.

INDIVIDUAL TREATMENT DURATION

Your doctor will decide how long you will be treated with MAVIRET®. Many patients take the medicine daily for 8 weeks. Depending on individual factors, treatment may last longer.

HOW TO TAKE MAVIRET®

Taking MAVIRET® correctly is important for the success of your treatment. Therefore, always take the medication exactly as prescribed by your doctor. Also follow these instructions:

- Take three MAVIRET® tablets together **once daily** throughout the treatment period. Do not miss a single day.
- Take MAVIRET® tablets **with a meal**. This helps your body absorb the active ingredients better. It does not matter how much fat and how many calories the food contains.
- Swallow the MAVIRET® **tablets whole**. Breaking, chewing, crushing, or dissolving the film-coated tablets may affect how the active ingredients are absorbed and the amount of MAVIRET® in your blood.

VOMITING AFTER TAKING THE MEDICINE

If you vomit after taking MAVIRET®, the amount of active ingredients in your blood may be reduced, which could make the treatment less effective.

Whether you should take another dose depends on whether your body had enough time to absorb the active ingredients:

- Take an additional dose of three MAVIRET® tablets if you vomit within three hours of taking your last dose.
- You do not need another dose if more than three hours have passed since your last dose. In that case, just remember to take your next regular dose at the usual time.

MISSED DOSE

Never take a double dose to make up for a missed dose of MAVIRET®. Whether you should take the missed dose depends on when you realize you have missed a dose:

- If you realize **within 18 hours** of the scheduled time that you have forgotten to **take** your tablets, take the missed dose **immediately**. Take the next dose at the usual time.
- If you realize **18 hours or more** after the scheduled time that you have forgotten to take your tablets, **do not take** the missed dose. Take the next scheduled dose at the usual time.

OVERDOSE

Contact your doctor immediately or go to a hospital if you accidentally take more than the recommended dose of MAVIRET®.

Take the medicine pack with you. This will allow the doctor to identify the medicine you have taken.

ABILITY TO DRIVE

MAVIRET® has no or only a negligible effect on the ability to drive safely and responsibly.

The ability to operate machinery is also not affected by the medication.

CONTRACEPTION, PREGNANCY, BREASTFEEDING

Seek medical advice regarding birth control, pregnancy, and breastfeeding before taking MAVIRET®.

- Certain contraceptives must not be taken with MAVIRET®.
- The effects of MAVIRET® during pregnancy are unknown. The medication is therefore not recommended for expectant mothers.
- It is unknown whether the active ingredients in the medication pass into breast milk.

Inform your doctor immediately if you become pregnant during treatment with MAVIRET®.

STORAGE AND EXPIRATION DATE

There are no special storage requirements for MAVIRET®.

Please do not use the medication after the expiration date. This date is indicated on the packaging after „Use by“ („Verwendbar bis“) and on each blister after „EXP.“



FURTHER INFORMATION

ABOUT MAVIRET®

You can also find information about MAVIRET® 100 mg/40 mg film-coated tablets for the treatment of hepatitis C infection at: **www.abbvie-care.de/maviret**

In addition, please carefully read the package leaflet for your medication before taking MAVIRET®.

If you have any specific questions about treatment with MAVIRET®, please ask your doctor or pharmacist.

ABOUT HEPATITIS C

How can you get infected with hepatitis C? When is a virus test conclusive? What treatment options are available and who can offer advice? Our website on hepatitis C infection offers answers: **www.abbvie-care.de/erkrankung/hepatitis-c**

On this page, you will also find tips for dealing with the condition in everyday life and can download additional patient brochures on hepatitis C free of charge.

GET SUPPORT!

Talking about hepatitis C isn't always easy. However, support and advice from others can be very helpful when dealing with the condition and undergoing treatment.

In the "Living with Hepatitis C" section on **www.abbvie-care.de/hepatitis-c** you will find ways to contact support groups and other useful addresses.

MY NOTES

AbbVie Deutschland GmbH & Co. KG
Mainzer Straße 81, 65189 Wiesbaden

Responsibility
corporate contribution network by natureOffice gmbh
2026
natureOffice.gmbh/DE-077-926617

DE-MAVI-260058 Last updated: July-2026

Note for the medical team:

It is not legally permitted to provide patients with MAVIRET® materials until MAVIRET® has been prescribed for them.

MAVIRET®
Glecaprevir/Pibrentasvir